Results 11 to 20 of about 283,224 (387)

5-fluorouracil and cardiotoxicity: a review [PDF]

Therapeutic Advances in Medical Oncology, 2018
Fluoropyrimidines such as 5-fluorouracil (5-FU) form the foundation of a wide variety of chemotherapy regimens. 5-FU is in fact the third most commonly used chemotherapeutic agent in the treatment of solid malignancies across the world. As with all chemotherapy, balancing the potential benefits of therapy against the risks of drug-related toxicity is ...
Joerg Herrmann, Ryan Khodadadi, Amir Lerman, Sakti Chakrabarti, Axel Grothey, Ronstan Lobo, Jaskanwal D. Sara, Muneeb Rehman, Jasvinder Kaur   +8 more
openaire   +5 more sources

Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines [PDF]

, 2013
The potential clinical utility of genetic markers associated with response to fluoropyrimidine treatment in colorectal cancer patients remains controversial despite extensive study.
A Fariña-Sarasqueta, A Loganayagam, A Ruzzo, A Ruzzo, A Yawata, A Zaniboni, Andreas-Claudius Hoffmann, Ann Barrett, B Glimelius, BA Jennings, Barbara A. Jennings, C Fernandez-Rozadilla, C Zhang, CE de Bock, CF Thorn, D Caronia, Daniel Epurescu, DB Longley, E Hitre, E Van Cutsem, G Willis, Gavin S. Chu, Gavin Willis, H Gellekink, H Taflin, I Weisberg, J Cassidy, Jane Skinner, K Derwinger, K Kawakami, K Kawakami, L Peter, L Sharp, M Boisdron-Celle, M Gusella, M Scartozzi, M Schwab, M Vignoli, ME Fernández-Contreras, Melanie Keane, MJ Deenen, MS Braun, MV Mandola, MV Mandola, MV Mandola, N Horie, P Frosst, R Pullmann Jr., RA Goodwin, Richard Turner, S Afzal, S Afzal, S Kaneda, T André, TV Perneger, V Sulzyc-Bielicka, W Ichikawa, W Scheithauer, WG Johnson, Yoon K. Loke   +59 more
core   +16 more sources

ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer

Journal of experimental & clinical cancer research : CR, 2021
Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success.
S. Dong, Shuo Liang, Zhiqiang Cheng, Xiang Zhang, L. Luo, Linchuan Li, Wenjie Zhang, Songhan Li, Qian Xu, Ming-wei Zhong, Jian-kang Zhu, Guangyong Zhang, Sanyuan Hu   +12 more
semanticscholar   +1 more source

Colchicine Ameliorates 5-Fluorouracil-Induced Cardiotoxicity in Rats

Oxidative Medicine and Cellular Longevity, 2022
Background and Objective. 5‐Fluorouracil is one of the most common chemotherapeutic agents used in the treatment of solid tumors. 5‐Fluorouracil‐associated cardiotoxicity is the second cause of cardiotoxicity induced by chemotherapeutic drugs after ...
Soheila Safarpour, Samaneh Safarpour, Marzieh Pirzadeh, A. Moghadamnia, A. Ebrahimpour, Fatemeh Shirafkan, Razieh Mansoori, S. Kazemi, M. Hosseini   +8 more
semanticscholar   +1 more source

Targeting DCLK1 overcomes 5‐fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β‐catenin pathway‐mediated cancer stemness

Clinical and Translational Medicine, 2022
Background To date, 5‐fluorouracil‐based chemotherapy is very important for locally advanced or metastatic colorectal cancer (CRC). However, chemotherapy resistance results in tumor recurrence and metastasis, which is a major obstacle for treatment of ...
Lanqing Wang, Lei Zhao, Zhenyu Lin, Dandan Yu, M. Jin, P. Zhou, Jinghua Ren, Jing Cheng, Kunyu Yang, Gang Wu, Zhang Tao, Dejun Zhang   +11 more
semanticscholar   +1 more source

Dynamic Hydrogels Based on Double Imine Connections and Application for Delivery of Fluorouracil

Frontiers in Chemistry, 2020
Dynamic hydrogels have been prepared by cross-linking of O-carboxymethyl chitosan (O-CMCS) with reversibly connected imino-PEGylated dynamers. The double imine chitosan/dynamer and dynamer bonds and were used to provide tighter structures and adaptive ...
Yan Zhang, Chi-Yen Pham, Rui Yu, Eddy Petit, Suming Li, Mihail Barboiu   +5 more
doaj   +1 more source

5-Fluorouracil combined with cisplatin via arterial induction for advanced T-stage nasopharyngeal carcinoma: A 10-year outcome of a phase I/II study

Frontiers in Oncology, 2022
Background and PurposeCurrently, there is no optimal dose recommendation for a 120-h continuous infusion of 5-fluorouracil via arterial cannulation for advanced T-stage nasopharyngeal carcinoma (NPC).
Li Xiang, Yun Zheng, PeiRong Ren, Sheng Lin, JianWen Zhang, QingLian Wen, LiJia He, ChangLing Shang, JingBo Wu   +8 more
doaj   +1 more source

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Hacker, U., Heinemann, Volker, Schalhorn, A., Stemmler, J., Weise, A.   +4 more
core   +1 more source

The rate of cardiac complications in patients receiving a 24-hour dose of 5-Fluorouracil [PDF]

مجله پزشکی دانشگاه علوم پزشکی تبریز, 2023
Background. Cardiotoxicity caused by fluoropyrimidines is an uncommon but potentially fatal complication. Its frequency has been 1.6 to 19% in previous studies. But there are no accurate statistics in Iran. The aim of this study was to determine the rate
Mostafa Davoodnataj, Mohsen Vakili Sadeghi, Naghmeh Zieaie Amiri, Majid Nabipour, Hemmat Gholinia Ahangar   +4 more
doaj   +1 more source

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

The Lancet, 2019
BACKGROUND Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and ...
S. Al-Batran, N. Homann, C. Pauligk, T. Goetze, J. Meiler, S. Kasper, H. Kopp, F. Mayer, G. Haag, K. Luley, U. Lindig, W. Schmiegel, M. Pohl, J. Stoehlmacher, G. Folprecht, S. Probst, N. Prasnikar, W. Fischbach, R. Mahlberg, J. Trojan, M. Koenigsmann, U. Martens, P. Thuss-Patience, M. Egger, A. Block, V. Heinemann, G. Illerhaus, M. Moehler, M. Schenk, F. Kullmann, D. Behringer, M. Heike, D. Pink, C. Teschendorf, Carmen Löhr, H. Bernhard, G. Schuch, V. Rethwisch, L. F. V. Weikersthal, J. Hartmann, M. Kneba, S. Daum, K. Schulmann, J. Weniger, S. Belle, T. Gaiser, F. Oduncu, M. Güntner, W. Hozaeel, Alexander Reichart, E. Jäger, T. Kraus, S. Mönig, W. Bechstein, M. Schuler, H. Schmalenberg, R. Hofheinz   +56 more
semanticscholar   +1 more source